

**Table 1. Mean and SEM for each genotype, operative, and treatment group**

	Wild-type				Calstabin-2 <sup>-/-</sup>			
	Sham		Myocardial infarction		Sham		Myocardial infarction	
	Placebo	JTV519	Placebo	JTV519	Placebo	JTV519	Placebo	JTV519
<b>Biometric values</b>								
Mice studied, <i>n</i>	10	8	16	13	9	10	11	16
Survival, %	100%	100%	81%	85%	100%	100%	64%	44%
Body weight, g	26.4±1.7	25.1±0.4	27.4±0.9	28.2±0.5	26.1±1.7	25.0±0.6	23.7±1.0	26.3±1.4
HW/BW, mg/g	5.2±0.3	5.3±0.2	9.0±0.6	7.7±0.4*	5.4±0.3	5.3±0.2	9.2±0.8	9.0±0.6
HW/TL, mg/mm	7.2±0.8	6.9±0.2	13.5±1.0	11.6±0.7*	6.9±0.1	6.9±0.3	12.3±0.9	12.2±1.0
Infarct size	0	0	39.0±1.9	40.7±3.7	0	0	41.8±4.7	46.4±5.1
<b>Echocardiography</b>								
LVPW, μm	76±2.7	74±2.8	76.9±2.3	76±2.3	73±2.3	71±2.3	76±3.1	73±2.9
EDD, mm	0.37±0.02	0.36±0.01	0.56±0.02	0.54±0.03	0.35±0.01	0.36±0.02	0.51±0.03	0.50±0.02
ESD, mm	0.28±0.02	0.26±0.01	0.46±0.04	0.47±0.03	0.24±0.01	0.24±0.01	0.44±0.03	0.45±0.02
EF, %	63.3±3.1	66.7±4.9	31.1±3.1	45.8±5.1*	69.1±3.1	68.6±2.8	31.5±5.7	31.9±3.1
FS, %	29.8±2.2	32.2±3.7	12.5±1.3	20.2±2.9*	30.5±5.0	33.3±2.0	12.9±2.8	12.8±1.5
EDV, μl	0.12±0.01	0.10±0.01	0.41±0.04	0.36±0.05	0.09±0.01	0.11±0.01	0.32±0.08	0.32±0.03
<b>Hemodynamic data</b>								
MAP, mmHg	75.9±6.4	70.2±3.4	67.1±2.7	68.5±3.4	76.3±5.1	72.8±4.7	67.9±4.7	68.2±4.7
HR, min <sup>-1</sup>	480±13	477±12	493±24	458±33	460±9	465±14	471±28	457±21
ESP, mmHg	94.8±2.7	93.9±1.5	84.0±3.1	92.7±5.4*	101±3.4	94.8±2.2	83.2±4.0	79.0±3.2
dP/dt(max)	8005±284	8878±350	6215±309	6826±735	8515±473	8030±322	5907±446	5726±314
dP/dt(min)	-6530±419	-7371±266	-5249±353	-5810±649	-7506±382	-7068±407	-4878±301	-4481±327

Data are presented as mean ± SEM. HW, heart weight; BW, body weight; TL, tibia length; LVPW, left ventricular posterior wall thickness; EDD, end-diastolic diameter; ESD, end-systolic diameter; EF, ejection fraction; FS, fractional shortening; EDV, end-diastolic volume; MAP, mean arterial blood pressure; HR, heart rate; ESP, end-systolic pressure.

\**P* < 0.05 placebo versus JTV519.